Clinical Trials

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT05411094 2026-04-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

18 enrolled

Pancreatic Neoplasms

NCT05630794 2026-04-13

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

36 enrolled

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05685602 2026-04-13

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

43 enrolled

Pancreatic Neoplasms

NCT05687123 2026-04-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

24 enrolled

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05691491 2026-04-13

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

58 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT05803382 2026-04-13

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

30 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06102902 2026-04-13

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT06364410 2026-04-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

48 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT06454383 2026-04-13

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

19 enrolled

Pancreatic Neoplasms

NCT06557733 2026-04-13

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Phase 2 Recruiting

38 enrolled

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT06696768 2026-04-13

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

24 enrolled

Colorectal Neoplasms

NCT06811116 2026-04-13

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

92 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Hepatocellular

NCT06995898 2026-04-13

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07147231 2026-04-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

86 enrolled

Colorectal Neoplasms

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07166406 2026-04-08

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

226 enrolled

Carcinoma, Hepatocellular

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT06050252 2026-04-03

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

Phase 2 Recruiting

27 enrolled

Resectable Intrahepatic Cholangiocarcinoma

NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

274 enrolled

Pancreatic Neoplasms

NCT06998940 2026-03-27

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT07324096 2026-03-27

AI-PACED

Phase NA Recruiting

100 enrolled

Phase EARLY_PHASE1 Recruiting

Pancreatic Ductal Adenocarcinoma

NCT07089940 2026-03-23

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

12 enrolled

Pancreatic Neoplasms

NCT06336902 2026-03-17

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

15 enrolled

Colorectal Neoplasms

NCT06408220 2026-03-13

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Phase NA Recruiting

240 enrolled

Stomach Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06349642 2026-03-12

ELEPHAS-04

Recruiting

324 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06269978 2026-03-10

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

24 enrolled

Colorectal Neoplasms

NCT06651580 2026-03-04

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

Recruiting

1,600 enrolled

Pancreatic Neoplasms, Pancreatitis, Pancreatitis, Chronic

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

85 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors